Such a well run company. We expected the expenses to increase with the ramp up of NNZ-2591 but it's just unreal our net FX gain for the quarter has covered our entire R&D spend over that same period. Another thing to note, it is good to see that the staff & general corporate expenses remaining reasonable (as a %) compared to our R&D spend which is a good sign.
- Forums
- ASX - By Stock
- NEU
- Ann: Q3 2023 quarterly activity and cash flow report
NEU
neuren pharmaceuticals limited
Add to My Watchlist
2.96%
!
$13.23

Ann: Q3 2023 quarterly activity and cash flow report, page-10
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$13.23 |
Change
0.380(2.96%) |
Mkt cap ! $1.626B |
Open | High | Low | Value | Volume |
$13.15 | $13.34 | $12.92 | $3.703M | 282.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 82 | $13.22 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.23 | 196 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 127 | 13.230 |
3 | 135 | 13.220 |
5 | 581 | 13.210 |
5 | 705 | 13.200 |
6 | 1263 | 13.190 |
Price($) | Vol. | No. |
---|---|---|
13.240 | 128 | 3 |
13.250 | 958 | 7 |
13.260 | 572 | 4 |
13.270 | 1420 | 5 |
13.280 | 1901 | 5 |
Last trade - 11.41am 18/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online